BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1116 related articles for article (PubMed ID: 26470790)

  • 1. Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
    Zekas E; Prossnitz ER
    BMC Cancer; 2015 Oct; 15():702. PubMed ID: 26470790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
    Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
    Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The G-protein-coupled estrogen receptor, a gene co-expressed with ERα in breast tumors, is regulated by estrogen-ERα signalling in ERα positive breast cancer cells.
    Pal U; Manjegowda MC; Singh N; Saikia S; Philip BS; Jyoti Kalita D; Kumar Rai A; Sarma A; Raphael V; Modi D; Chandra Kataki A; Mukund Limaye A
    Gene; 2023 Aug; 877():147548. PubMed ID: 37279863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
    Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC
    Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ER-mediated anti-tumor effects of shikonin on breast cancer.
    Yang Y; Gao W; Tao S; Wang Y; Niu J; Zhao P; Rao C; Yang L
    Eur J Pharmacol; 2019 Nov; 863():172667. PubMed ID: 31545985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
    Li Y; Birnbaumer L; Teng CT
    Mol Endocrinol; 2010 May; 24(5):969-80. PubMed ID: 20211987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells.
    Lappano R; Rosano C; Santolla MF; Pupo M; De Francesco EM; De Marco P; Ponassi M; Spallarossa A; Ranise A; Maggiolini M
    Curr Cancer Drug Targets; 2012 Jun; 12(5):531-42. PubMed ID: 22414008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling.
    Revankar CM; Bologa CG; Pepermans RA; Sharma G; Petrie WK; Alcon SN; Field AS; Ramesh C; Parker MA; Savchuk NP; Sklar LA; Hathaway HJ; Arterburn JB; Oprea TI; Prossnitz ER
    Cell Chem Biol; 2019 Dec; 26(12):1692-1702.e5. PubMed ID: 31706983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness.
    Sisci D; Maris P; Cesario MG; Anselmo W; Coroniti R; Trombino GE; Romeo F; Ferraro A; Lanzino M; Aquila S; Maggiolini M; Mauro L; Morelli C; Andò S
    Cell Cycle; 2013 Nov; 12(21):3405-20. PubMed ID: 24047697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation.
    Molina L; Bustamante F; Ortloff A; Ramos I; Ehrenfeld P; Figueroa CD
    Front Endocrinol (Lausanne); 2020; 11():563165. PubMed ID: 33117280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen induces toxicity, causes autophagy, and partially reverses dexamethasone resistance in Jurkat T cells.
    Torres-López L; Maycotte P; Liñán-Rico A; Liñán-Rico L; Donis-Maturano L; Delgado-Enciso I; Meza-Robles C; Vásquez-Jiménez C; Hernández-Cruz A; Dobrovinskaya O
    J Leukoc Biol; 2019 May; 105(5):983-998. PubMed ID: 30645008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cell line competence for studies of pharmacological GPR30 modulation.
    Sousa C; Ribeiro M; Rufino AT; Leitão AJ; Mendes AF
    J Recept Signal Transduct Res; 2017 Apr; 37(2):181-188. PubMed ID: 27401115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer.
    Santolla MF; Avino S; Pellegrino M; De Francesco EM; De Marco P; Lappano R; Vivacqua A; Cirillo F; Rigiracciolo DC; Scarpelli A; Abonante S; Maggiolini M
    Cell Death Dis; 2015 Jul; 6(7):e1834. PubMed ID: 26225773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NHERF1, a novel GPER associated protein, increases stability and activation of GPER in ER-positive breast cancer.
    Meng R; Qin Q; Xiong Y; Wang Y; Zheng J; Zhao Y; Tao T; Wang Q; Liu H; Wang S; Jiang WG; He J
    Oncotarget; 2016 Aug; 7(34):54983-54997. PubMed ID: 27448983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
    Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
    BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of 3D MCF-12A breast cell cultures by estrogens--an in vitro model for ER-mediated changes indicative of hormonal carcinogenesis.
    Marchese S; Silva E
    PLoS One; 2012; 7(10):e45767. PubMed ID: 23056216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Breast Cancer Inhibitors Specific for G Protein-Coupled Estrogen Receptor (GPER)-Expressing Cells.
    Aiello F; Carullo G; Giordano F; Spina E; Nigro A; Garofalo A; Tassini S; Costantino G; Vincetti P; Bruno A; Radi M
    ChemMedChem; 2017 Aug; 12(16):1279-1285. PubMed ID: 28520140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
    J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.